Background: Indolent T-cell proliferative disorder of the GIT is a rare and provisional entity in the revised WHO 2016 classification. The patients usually have prolonged survival with persistent disease even without any treatment.

Case Presentation: The 46 years old male patient has been followed up for more than 6 years without chemotherapy. Repeated gastrointestinal biopsies showed expansion of the lamina propria extending to the submucosa by small to medium sized lymphocytes with minimal cytologic atypia. The lymphoid cells were positive for CD3, CD43, TIA-1, CD2, CD7 and the B-cell marker CD20; but negative for CD4, CD8, PAX5, CD56, cyclinD1, granzyme (GraB) and Epstein Barr virus-encoded RNA (EBER). Ki-67(MIB1) index was less than 10%. Molecular tests demonstrated a clonal rearrangement for T-cell receptor γ (TCR γ) gene but immunoglobulin chain (IgH, IgK, IgL) gene remained germline. Recognition of possible aberrant CD20 expression in indolent T-cell LPD is important to avoid potential diagnostic pitfall and improper treatment.

Conclusions: We present an unusual case of indolent T-cell lymphoproliferative disorder with aberrant CD20 expression, Recognition of this unusual immunophenotype of indolent T-cell LPD of GI helps to eschew misdiagnosis of B-cell and other high grade lymphomas and inappropriate aggressive treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195681PMC
http://dx.doi.org/10.1186/s13000-018-0762-4DOI Listing

Publication Analysis

Top Keywords

indolent t-cell
20
aberrant cd20
12
cd20 expression
12
unusual case
8
t-cell lymphoproliferative
8
lymphoproliferative disorder
8
disorder aberrant
8
t-cell lpd
8
t-cell
6
indolent
5

Similar Publications

Article Synopsis
  • FT596 is a novel cancer therapy using iPSC-derived CAR NK cells targeting CD19, designed to assess its safe dosage and effectiveness alone and with rituximab in patients with B-cell lymphoma.
  • This phase 1 trial involved patients with relapsed or refractory B-cell lymphoma, administering FT596 after chemotherapy, with separate regimens for those receiving rituximab and those who did not.
  • The study measured potential side effects while determining the optimal dose of FT596 and allowed modifications to the treatment based on patient tolerance and response.
View Article and Find Full Text PDF

Indolent clonal lymphoid disorders are not recognized as lymphomas as they generally need no systemic treatment, and depending on the lesion, need only limited clinical follow-up. These lesions are usually incidentally diagnosed during the work up for other disease. The recognition of indolent clonal lymphoid disorders is important to avoid misdiagnosis as lymphoma and unnecessary treatment.

View Article and Find Full Text PDF

Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.

Leuk Lymphoma

January 2025

First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.

Article Synopsis
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare type of lymphoma, making up about 5% of Hodgkin lymphoma cases, and shares some characteristics with B-cell non-Hodgkin lymphoma.
  • NLPHL is typically diagnosed at early stages and has a slow progression, leading to excellent long-term survival rates for most patients.
  • Treatment mainly mirrors classical Hodgkin lymphoma but may include rituximab; future strategies could involve innovative therapies like CAR T-cell therapy and bispecific antibodies.
View Article and Find Full Text PDF

Aim: To evaluate predictive chest computed tomography (CT) findings associated with the development of adult T-cell leukemia/lymphoma (ATLL) in human T-lymphotropic virus type I (HTLV-1) carriers.

Materials And Methods: This retrospective study examined 171 adult T-cell leukemia/lymphoma and 158 HTLV-1 carriers who were treated from November 2004 to April 2021. The radiological features of 888 chest CT scans in total were retrospectively assessed by two chest radiologists who were unaware of the underlying diagnoses and compared between the groups.

View Article and Find Full Text PDF

Systemic hydroa vacciniforme lymphoproliferative disorder in a patient with chronic active EBV infection.

BMJ Case Rep

December 2024

Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Hydroa vacciniforme lymphoproliferative disorders (HVLPD) fall within the clinical spectrum of chronic active epstein barr virus (EBV) disease (CAEBVD), ranging from localised and/or indolent forms (classic HVLPD) to systemic disease with fever, hepatosplenomegaly and lymphadenopathy (systemic HVLPD). A preadolescent male with 47XYY, multicystic dysplastic kidney, autism spectrum disorder and Attention-deficit/hyperactivity disorder (ADHD) presented with photodistributed non-pruritic, non-painful necrotic papulovesicles accompanied by non-febrile intermittent fatigue and lymphadenopathy. The patient had a history of EBV pneumonia in infancy confirmed by CT scan and was later diagnosed with CAEBV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!